{rfName}
Im

Indexed in

License and use

Icono OpenAccess

Citations

19

Altmetrics

Grant support

This study was funded by Pfizer, S.L.U. Medical writing assistance was provided by Esther Tapia, PhD and was founded by Pfizer. The authors gratefully say thanks to Ma Luz Samaniego for his help with the statistical analyses.

Analysis of institutional authors

Marrupe, DavidAuthor

Share

Publications
>
Article

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

Publicated to:Bmc Cancer. 16 135- - 2016-02-22 16(), DOI: 10.1186/s12885-016-2084-9

Authors: Lainez, Nuria; Garcia-Donas, Jesus; Esteban, Emilio; Puente, Javier; Isabel Saez, M; Gallardo, Enrique; Pinto-Marin, Alvaro; Vazquez-Estevez, Sergio; Leon, Luis; Garcia-Carbonero, Icar; Suarez-Rodriguez, Cristina; Molins, Carmen; Climent-Duran, Miguel A; Lazaro-Quintela, Martin; Gonzalez del Alba, Aranzazu; Jose Mendez-Vidal, Maria; Chirivella, Isabel; Afonso, Francisco J; Lopez-Brea, Marta; Sala-Gonzalez, Nuria; Domenech, Montserrat; Basterretxea, Laura; Santander-Lobera, Carmen; Gil-Arnaiz, Irene; Fernandez, Ovidio; Caballero-Diaz, Cristina; Mellado, Begona; Marrupe, David; Garcia-Sanchez, Jose; Sanchez-Escribano, Ricardo; Fernandez Parra, Eva; Villa Guzman, Jose C; Martinez-Ortega, Esther; Belen Gonzalez, Maria; Moran, Marina; Suarez-Paniagua, Beatriz; Lecumberri, Maria J; Castellano, Daniel

Affiliations

Abstract

Background: The impact of such recommendations after their implementation of guidelines has not usually been evaluated. Herein, we assessed the impact and compliance with the Spanish Oncology Genitourinary Group (SOGUG) Guidelines for toxicity management of targeted therapies in metastatic renal cell carcinoma (mRCC) in daily clinical practice.Methods: Data on 407 mRCC patients who initiated first-line targeted therapy during the year before and the year after publication and implementation of the SOGUG guideline program were available from 34 Spanish Hospitals. Adherence to SOGUG Guidelines was assessed in every cycle.Results: Adverse event (AE) management was consistent with the Guidelines as a whole for 28.7 % out of 966 post-implementation cycles compared with 23.1 % out of 892 pre-implementation cycles (p = 0.006). Analysis of adherence by AE in non-compliant cycles showed significant changes in appropriate management of hypertension (33 % pre-implementation vs. 44.5 % post-implementation cycles; p < 0.0001), diarrhea (74.0 % vs. 80.5 %; p = 0.011) and dyslipemia (25.0 % vs. 44.6 %; p < 0.001).Conclusions: Slight but significant improvements in AE management were detected following the implementation of SOGUG recommendations. However, room for improvement in the management of AEs due to targeted agents still remains and could be the focus for further programs in this direction.

Keywords

Adverse eventsAgedAntineoplastic agentsCarcinoma, renal cellEfficacyEndothelial growth-factorFemaleGuideline adherenceGuidelinesHumansHypertensionKidney neoplasmsMaleMiddle agedMolecular targeted therapyNeoplasm metastasisPractice guidelines as topicRenal cell carcinomaRenal-cell carcinomaSafetySorafenibSpainSu11248SunitinibTargeted therapyTreatment patternsTyrosine kinase inhibitor

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Bmc Cancer due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2016, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.38, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-29, the following number of citations:

  • WoS: 7
  • Scopus: 8
  • Europe PMC: 4
  • OpenCitations: 7

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-29:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 58.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 58 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 5.25.
  • The number of mentions on the social network X (formerly Twitter): 10 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: China.